Pharmakologische renoprotektion bei kindern mit chronischer niereninsuffizienz

Translated title of the contribution: Pharmacological renoprotection in children with chronic kidney disease

O. Mehls, E. Wühl, F. Schaefer, A. Anarat, A. Bakkaloglu, F. Ozaltin, A. Peco-Antic, U. Querfeld, J. Gellermann, P. Sallay, D. Drozdz, K. E. Bonzel, A. M. Wingen, A. Zurowska, I. Balasz, F. Perfumo, A. Canepa, D. E. Müller-Wiefel, K. Zepf, G. OffnerB. Enke, C. Hadtstein, U. Berg, G. Celsi, S. Emre, A. Sirin, I. Bilge, S. Çaliskan, S. Mir, E. Serdaroglu, C. Greiner, H. Eichstädt, S. Wygoda, K. Hohbach-Hohenfeliner, N. Jeck, G. Klaus, A. Appiani, G. Ardissino, S. Testa, G. Montini, P. Niaudet, M. Charbit, J. Dusek, A. Caldas-Afonso, A. Teixeira, S. Picca, C. Matteucci, M. Wigger, M. Fischbach, J. Terzic, J. Fydryk, T. Urasinski, R. Coppo, L. Peruzzi, A. Jankauskiene, M. Litwin, M. Abuauba, R. Grenda, K. Arbeiter, T. J. Neuhaus

Research output: Contribution to journalArticle

Abstract

Hypertension and proteinuria are tightly correlated with the progression rate of chronic renal failure (CRF). A low protein diet did not improve the progression rate in adults and children with CKD within an observation period of 3 years. In contrast, intention-to-treat studies in adults have shown that a pharmacologic blockade of the renin-angiotensin system significantly reduces the progression rate of CRF. Because of important differences in primary renal diseases, results and recommendations of pharmacological renoprotection in adults cannot be extended to children. Therefore, the effect of strict blood pressure control and ACE inhibition on progression of CRF in 400 pediatric patients are currently studied over an observation period of 5 years in a randomized, prospective intention-to-treat study (ESCAPE Trial). The study will be finalized at the end of 2007. Renal hypodysplasia and hereditary nephropathies were responsible for more than 80% of chronic kidney diseases in children. Preliminary results demonstrate that ACE inhibition reduces blood pressure and proteinuria also in children with congenital renal diseases and reduces the progression rate of CRF. In addition, the ESCAPE Trial gives important new information on the prevalence of mutations in renal developmental genes in renal hypodysplasia. It also describes early cardiovascular changes in young patients with CKD and without cardiovascular comorbid factors.

Translated title of the contributionPharmacological renoprotection in children with chronic kidney disease
Original languageGerman
Pages (from-to)6-11
Number of pages6
JournalNieren- und Hochdruckkrankheiten
Volume36
Issue number1
Publication statusPublished - Jan 2007

Keywords

  • ACE inhibition
  • Arterial hypertension
  • Cardiovascular changes
  • Chronic kidney disease
  • ESCAPE trial
  • Genetics
  • Proteinuria

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Fingerprint Dive into the research topics of 'Pharmacological renoprotection in children with chronic kidney disease'. Together they form a unique fingerprint.

  • Cite this

    Mehls, O., Wühl, E., Schaefer, F., Anarat, A., Bakkaloglu, A., Ozaltin, F., Peco-Antic, A., Querfeld, U., Gellermann, J., Sallay, P., Drozdz, D., Bonzel, K. E., Wingen, A. M., Zurowska, A., Balasz, I., Perfumo, F., Canepa, A., Müller-Wiefel, D. E., Zepf, K., ... Neuhaus, T. J. (2007). Pharmakologische renoprotektion bei kindern mit chronischer niereninsuffizienz. Nieren- und Hochdruckkrankheiten, 36(1), 6-11.